The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2024 | Insights into the uses of ibrutinib for patients with Waldenström’s macroglobulinemia
Ramón Garcia Sanz, MD, PhD, Hospital Universitario de Salamanca, Salamanca, Spain, discusses the use of ibrutinib, a BTK inhibitor, in the treatment of patients with Waldenström’s macroglobulinemia (WM). Ibrutinib has shown the best response rates in WM after chemoimmunotherapy and can be used as a first-line treatment when chemoimmunotherapy is not manageable. It does, however, have side effects such as arrhythmias and hypertension, which can be hard to manage. Research is therefore being conducted to mitigate these toxicities. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
